UK Markets close in 2 hrs 16 mins

​​​​​​​Supervisory Board of Epigenomics AG Appoints Dr. Andrew Lukowiak as President and Chief Scientific Officer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

DGAP-News: Epigenomics AG / Key word(s): Personnel
18.11.2021 / 08:00
The issuer is solely responsible for the content of this announcement.

Supervisory Board of Epigenomics AG Appoints Dr. Andrew Lukowiak as President and Chief Scientific Officer


Berlin (Germany) and San Diego, CA (U.S.A.), November 18, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company"), the German-American cancer molecular diagnostics company, announced today that the Supervisory Board appointed Dr. Andrew Lukowiak as President and Chief Scientific Officer with effect from December 1, 2021. Dr. Lukowiak, who has held senior management positions in the U.S. molecular diagnostics industry, will become a member of the Executive Board of Epigenomics and oversee Research and Development and Operations.

Dr. Lukowiak (49) has over 20 years of management experience in the molecular diagnostics and life sciences industries. Prior to joining Epigenomics, Andrew served as CEO and Board Member for Millennium Health, a leading specialty toxicology laboratory. Dr. Lukowiak was also Chief Operating Officer of AltheaDx Inc., where he led the development, validation and launch of multiple Real-Time PCR tests for a broad array of disease states. Additionally, he was a senior R&D executive at GenMark Diagnostics and Hologic, where he was responsible for both PMA and 510(k) cleared products including the support and automation of an HPV test for cervical cancer. Dr. Lukowiak earned his doctorate in Genetics from the University of Georgia and his Bachelor of Science in Biology from Pennsylvania State University.

Heino von Prondzynski, Chairman of the Supervisory Board, stated: "The Supervisory Board is excited to add the significant executive management, clinical and technical expertise that Andrew brings to the Executive Board of Epigenomics AG. Dr. Lukowiak has continually demonstrated the ability to deliver innovative tests through the FDA and the reimbursement process that have then led to commercial success. His breadth and depth of experience is ideally suited for Epigenomics to successfully execute the strategic plan for Epi proColon "Next-Gen"."

"I am excited to join the Epigenomics team and execute the plan for Epi proColon Next-Gen"," said Dr. Lukowiak. "Epigenomics' "Next-Gen" blood-based cancer test has the potential to significantly improve colon cancer screening rates and save lives. The company's leadership and innovation in liquid biopsy is an ideal platform to deliver an easy-to-use Real-time PCR based solution for hospital-based laboratories."
 

About Epigenomics
Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer. Based on its proprietary biomarker technology for the detection of methylated DNA, Epigenomics develops and markets blood tests for various cancer indications with high unmet medical need. Epigenomics' lead product is the blood test Epi proColon(R) for the early detection of colorectal cancer. Epi proColon is approved by the U.S. Food and Drug Administration (FDA) and is marketed in the United States and Europe as well as other selected countries. HCCBloodTest, a blood test for the detection of liver cancer, have received the CE Mark for marketing in Europe.

For further information please visit www.epigenomics.com.
 

Contact:
Company

Epigenomics AG, Geneststrasse 5, 10829 Berlin,
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, E-Mail: contact@epigenomics.com

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, E-Mail: ir@epigenomics.com

 

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any expected results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 


18.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Epigenomics AG

Geneststraße 5

10829 Berlin

Germany

Phone:

+49 30 24345-0

Fax:

+49 30 24345-555

E-mail:

ir@epigenomics.com

Internet:

www.epigenomics.com

ISIN:

DE000A3H2184

WKN:

A3H218

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1250065


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting